TD Cowen Maintains Buy on Cellebrite DI, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Shaul Eyal maintains a Buy rating on Cellebrite DI and raises the price target from $20 to $23, indicating confidence in the company's future performance.
September 23, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Shaul Eyal has reiterated a Buy rating for Cellebrite DI and increased the price target from $20 to $23, suggesting a positive outlook for the company's stock.
The increase in price target from $20 to $23 by TD Cowen indicates a positive outlook for Cellebrite DI, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100